Living with HSH: The Path Forward
At a Glance
Children with HSH often have encouraging long-term seizure control when magnesium treatment is taken consistently, but care remains lifelong. Blood monitoring, developmental follow-up, testing for at-risk siblings, and family support help maintain stability.
Receiving an HSH diagnosis is often a moment of profound relief followed by the realization that managing this condition is a lifelong commitment. While the “crisis” phase of neonatal seizures may be over, the focus now shifts to maintaining stability, supporting development, and navigating the day-to-day realities of a rare chronic condition [1][2].
The Long-Term Outlook
For children diagnosed early and treated consistently, survival and long-term seizure control are generally very encouraging [1][3]. In small follow-up studies, those who maintained their magnesium therapy frequently remained free of the severe seizures that characterized their infancy [4][5]. Many children with HSH go on to attend mainstream schools, participate in sports, and transition successfully into adult care [3][6].
However, “stable” does not always mean “symptom-free,” and outcomes vary. Even with good adherence to treatment, some children may experience neurodevelopmental challenges. Research in small cohorts has identified several potential comorbidities in HSH patients, including:
- Specific Learning Difficulties: Challenges with reading, writing, or math may emerge as the child reaches school age [1].
- ADHD: Attention-Deficit/Hyperactivity Disorder has been noted in some long-term follow-up cohorts [1].
- Developmental Delay: Approximately 23% of children in one published series were reported to have some form of developmental delay, though it is often unclear if this stems from the initial seizures or the underlying mineral imbalance [7].
Because of these risks, routine developmental surveillance is sensible. Formal speech, occupational, or behavioral assessments are utilized based on the child’s age, clinical findings, and family concerns [1].
The Challenge of Lifelong Adherence
Staying consistent with high-dose oral magnesium is the most critical part of managing HSH, but it is also the most challenging. Unlike many medications, the doses required for HSH are “supraphysiologic,” meaning they are much higher than what a body typically needs from the diet [8].
- Digestive Toll: Chronic diarrhea is the most frequent barrier to adherence [6][9]. Over years of treatment, the constant digestive upset can be exhausting for both the child and the caregivers.
- The “Borderline” Reality: You may find that your child’s blood magnesium levels remain “borderline low” even when they are taking their medication perfectly [9][10]. It is important to remember that the goal is not a perfect number on a lab report, but a child who is growing, learning, and remaining free of seizures and muscle spasms [9][7].
Protecting the Family: Sibling Screening
Because HSH is an autosomal recessive condition, if both biological parents are confirmed carriers, any sibling of your child has a 25% (1 in 4) chance of inheriting the same condition with each pregnancy [11][12].
While HSH typically presents in the first few months of life, symptoms can sometimes be delayed until the toddler years [11]. Prompt genetic counseling and specialist-directed testing for at-risk siblings is highly recommended. Targeted genetic testing for the family’s known pathogenic variants provides the most definitive answer, as one normal baseline magnesium test at birth may not exclude a child before biochemical symptoms appear [3][8]. Identifying the condition early helps prevent severe electrolyte symptoms and seizure complications [4].
The Psychological Reality
Managing HSH places a unique psychological burden on a family. The “diagnostic odyssey” you likely endured can leave a lasting emotional impact, and the transition to chronic care brings new stressors [2].
- Monitoring Fatigue: Frequent blood draws are a necessary part of the first few years of life to ensure the magnesium dose is correct. For a toddler, this can lead to “needle phobia” or medical anxiety. For parents, seeing their child in distress during these procedures is a significant source of stress [2].
- Parent-Provider Relationships: Because HSH is so rare, you may find yourself “educating” ER doctors or school nurses about your child’s needs. Having a strong, collaborative relationship with a primary pediatric nephrologist, endocrinologist, or metabolic geneticist is essential for coordinating this care [2][13].
Despite these hurdles, many families find that with a structured routine and a supportive medical team, HSH becomes a manageable part of life rather than its defining feature.
Common questions in this guide
What is the long-term outlook for a child with HSH?
Can HSH affect my child’s learning or development?
Why might my child’s magnesium result stay slightly low during treatment?
How can we make lifelong magnesium treatment easier to follow?
Should my other children be tested for HSH?
What ongoing monitoring does a child with HSH need?
What support can help families living with HSH?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Development and learning
Would formal speech or behavioral assessments be useful for my child?
Side effects
Are there ways to ease diarrhea from magnesium treatment?
Lab monitoring
How often should my child's blood magnesium levels be checked?
Get notified when new evidence is published on Primary hypomagnesemia with secondary hypocalcemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Long-term Clinical Follow-up of Patients with Familial Hypomagnesemia with Secondary Hypocalcemia
Bayramoğlu E, Keskin M, Aycan Z, et al.
Journal of clinical research in pediatric endocrinology 2021; (13(3)):300-307 doi:10.4274/jcrpe.galenos.2021.2020.0192.
PMID: 33565749 - 2
Genetic Testing in the Pediatric Nephrology Clinic: Understanding Families' Experiences.
Nevin SM, McLoone J, Wakefield CE, et al.
Journal of pediatric genetics 2022; (11(2)):117-125 doi:10.1055/s-0040-1721439.
PMID: 35769952 - 3
A novel TRPM6 variant (c.3179T>A) causing familial hypomagnesemia with secondary hypocalcemia.
Lomelino-Pinheiro S, Margarida B, Lages AS
Endocrinology, diabetes & metabolism case reports 2020; (2020()).
PMID: 32369769 - 4
Clinical Spectrum of Primary Hypomagnesemia with Secondary Hypocalcemia due to TRPM6 Mutation.
Aftab S, Anjum MN, Aslam N, et al.
Hormone research in paediatrics 2026; (99(7)):1045-1050 doi:10.1159/000547303.
PMID: 40853861 - 5
Familial Hypomagnesemia With Secondary Hypocalcemia: A Case Report.
Gazzaz N, Alghamdi M
Cureus 2021; (13(11)):e19847 doi:10.7759/cureus.19847.
PMID: 34963857 - 6
A Novel Homozygous Mutation in the Transient Receptor Potential Melastatin 6 Gene: A Case Report.
Altıncık A, Schlingmann KP, Tosun MS
Journal of clinical research in pediatric endocrinology 2016; (8(1)):101-4 doi:10.4274/jcrpe.2254.
PMID: 26759217 - 7
Three cases of hereditary hypomagnesemia with secondary hypocalcemia caused by novel TRPM6 gene mutations and a literature review.
Yang M, Zheng Z, Shan X, Luo Y
Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(9)):917-925 doi:10.1515/jpem-2026-0185.
PMID: 42324811 - 8
Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6.
Astor MC, Løvås K, Wolff AS, et al.
Endocrine connections 2015; (4(4)):215-22 doi:10.1530/EC-15-0066.
PMID: 26273099 - 9
Treatment Difficulties in Hypomagnesemia Secondary to the Transient Receptor Potential Melastatin 6 Gene: A Case Report with Novel Mutation
Yücel H, Genç Sel Ç, Kasapkara ÇS, et al.
Journal of clinical research in pediatric endocrinology 2021; (13(1)):114-118 doi:10.4274/jcrpe.galenos.2020.2020.0004.
PMID: 32302086 - 10
[A case report of primary hypomagnesemia with secondary hypocalcemia caused by TRPM6 gene variants].
Zhou MY, Tang XJ, Lin SX, Chen CF
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2026; (28(1)):107-110 doi:10.7499/j.issn.1008-8830.2507066.
PMID: 41582756 - 11
Case Report: Novel TRPM6 Mutations Cause Hereditary Hypomagnesemia With Secondary Hypocalcemia in a Chinese Family and a Literature Review.
Han Y, Zhao Y, Wang H, Huo L
Frontiers in pediatrics 2022; (10()):912524 doi:10.3389/fped.2022.912524.
PMID: 35903165 - 12
Familial hypomagnesemia with secondary hypocalcemia: a novel TRPM6 mutation associated with treatment-resistant migraine in a North African family.
Paola PM, Gianni C, Emanuele M, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(10)).
PMID: 42830330 - 13
How to Suspect and Approach Patients With Genetic Tubular Disease.
Karet Frankl FE
Seminars in nephrology 2025; (45(4)):151654 doi:10.1016/j.semnephrol.2025.151654.
PMID: 40681419
This page is for informational purposes only and does not constitute medical advice. Your child’s pediatric nephrologist, endocrinologist, or metabolic geneticist should guide magnesium dosing, monitoring, and genetic testing.